Magic Molecules
Michael D. Lam
Associate Editor
Analysts and consultants dip into the pipeline to select 25 products that are going to make a difference for pharma—and patients.
Forecast 2005
Will this be the year drug importation staggers the industry? Will the sales force keep growing? What's next in technology? Our panel of prophets answer these questions and more.
Unleash the Dragonc
Zhu Shen
BioForesight
All those patients. All those scientists. And all those US-trained entrepreneurs looking for partners. No wonder pharma is increasingly turning to China.
Conflict Resolution: A Pharm Exec Conference Report
Sibyl Shalo
Senior Editor
New standards for pharma-supported medical education aren't as impossible as they seem. ACCME's Murray Kopelow explains why.
The Ethics of Pharma
A Pharm Exec Roundtable
If ethics were just about telling wrong from right, it would be hard enough. The trickiest part, these experts say, is choosing between right and right.
News
The managed-care backlash is easing
Data
Would you enroll your child in a clinical trial?
Thought Leaders
Mark Scheineson, a former FDA official, urges pharma companies to contest class-action suits aggressively.
Washington Report
Bush's re-election was good news for pharma, but there are still some important issues for the next four years.
Jill Wechsler
Global Report
In Britain, a new law lops another 7 percent off drug prices—by setting limits on profits.
Sarah Houlton
Legal Forum
Some courts are rejecting "grouping" of lawsuits against pharma. Here's why that's good news.
William M. Janssen
Saul Ewing LLP
Leadership
Every day you get to choose the attitude you'll take. To succeed, choose persistence.
Sander A. Flaum
Flaum Partners
Direct to Consumer
It's cheap, targeted, and mobile, and people spend 20 hours a week listening to it. Remember radio?
Stephen Friedman
Interep Innovations Marketing Group
Alternative Media
Electronic medical records can enhance physician involvement in patient adherence.
Devin S. Paullin and Paul Foley
Allscripts Healthcare Solutions
Marketing to Professionals
It's true—you can measure the performance of a medical science liaison.
Jane Chin
Medical Science Liaison Institute
Public Relations
Weakness in equity markets means that executives are making a beeline for the buy side. What's your strategy?
Brooke Wagner
Citigate Financial Intelligence
Have you checked all the basics? Check'em again.
Melissa R. Dull and Lynnell R. Wakley
P.S. Solutions
From the Editor
We all want safe drugs, even when we demand risky ones. That's consistent, right?
Patrick Clinton
Editor-in-Chief
Back Page
Can Vioxx be the catalyst to change how we manage risk?
Murray L. Aitken
IMS Health
People Update
Calendar of Events
Advertisers Index
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.